Exscientia starts trials of first AI-derived cancer immunotherapyExscientia was the first company to start human trials of a new drug designed using artificial intelligence (AI) Share XExscientia starts trials of first AI-derived cancer immunotherapyhttps://pharmaphorum.com/news/exscientia-starts-trials-of-first-ai-derived-cancer-immunotherapy/
Alzheimer’s Research UK starts AI-based drug hunt with ExscientiaMedical charity Alzheimer’s Research UK has teamed up with artificial intelligence specialist Exscientia to find new drug treatments Share XAlzheimer’s Research UK starts AI-based drug hunt with Exscientiahttps://pharmaphorum.com/news/alzheimers-research-uk-starts-ai-based-drug-hunt-with-exscientia/
AZ drug hunter Garry Pairaudeau joins AI specialist ExscientiaDrug discovery firm Exscientia has beefed up its leadership team with the appointment of former AstraZeneca scientist Dr Share XAZ drug hunter Garry Pairaudeau joins AI specialist Exscientiahttps://pharmaphorum.com/news/az-drug-hunter-garry-pairaudeau-joins-ai-specialist-exscientia/
Blue Oak taps AI specialist Exscientia for CNS drug discoveryUS startup Blue Oak Pharma has joined a lengthening list of companies turning to Exscientia of the UK Share XBlue Oak taps AI specialist Exscientia for CNS drug discoveryhttps://pharmaphorum.com/news/blue-oak-taps-ai-specialist-exscientia-for-cns-drug-discovery/
Record number of health firms feature in UK top 100 private tech listA record number of health and medtech companies have been included in the Sunday Times Sage Tech Track Share XRecord number of health firms feature in UK top 100 private tech listhttps://pharmaphorum.com/news/babylon-among/
Could AI avert a future coronavirus pandemic?Could AI prevent future pandemics by developing an armoury of drugs that work against all coronaviruses? This is Share XCould AI avert a future coronavirus pandemic?https://pharmaphorum.com/news/could-ai-avert-a-future-coronavirus-pandemic/
AI drug discovery firm Exscientia gets $60M cash injectionUK artificial intelligence specialist Exscientia has topped up its coffers with a $60 million Series C funding round Share XAI drug discovery firm Exscientia gets $60M cash injectionhttps://pharmaphorum.com/news/ai-drug-discovery-firm-exscientia-gets-60m-cash-injection/
AI specialist Exscientia signs drug discovery tie-up with BayerUK artificial intelligence company Exscientia has added another big pharma company to its partner roster, with Bayer seeking Share XAI specialist Exscientia signs drug discovery tie-up with Bayerhttps://pharmaphorum.com/news/ai-specialist-exscientia-signs-drug-discovery-tie-up-with-bayer/
AI specialist Exscientia forms rare disease JV with RallyBioUK artificial intelligence (AI) drug discovery company Exscientia has formed another R&D alliance, this time in the area Share XAI specialist Exscientia forms rare disease JV with RallyBiohttps://pharmaphorum.com/news/ai-specialist-exscientia-forms-rare-disease-jv-with-rallybio/
